Darolutamide leads to metastasis-free survival of 40.4 months in non-metastatic CRPC

Bayer and Orion reported detailed data on Feb. 14 from the Phase III ARAMIS trial to treat non-metastatic castration-resistant prostate cancer showing that darolutamide

Read the full 247 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE